(terbinafine · DailyMed)
FUNGISIL M
TERBINAFINE HYDROCHLORIDE AND MOMETASONE FUROATE CREAM
What it does
Mometasone is a corticosteroid used to reduce inflammation and treat various allergic and skin conditions.
Commonly used for: allergic rhinitis (hay fever), asthma, skin conditions like eczema and psoriasis
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.
Source this medicineRegistration & product details
Source: Pharmacy and Poisons Board · fetched 2026-01-28 20:15:35 · updated 2026-10-23 02:24:36
Drug Interactions
63Severe (1)
Mifamurtide - decreases efficacy
Corticosteroidsarepredictedtodecreasetheefficacyof mifamurtide.Avoid.rTheoretical
Moderate (29)
Anticholinesterases, Centrally Acting - increases exposure
Terbinafine is predicted to increase the exposure to anticholinesterases, centrally acting (galantamine). Monitor and adjust dose.
Antipsychotics, Second Generation - increases exposure
Terbinafine is predicted to increase the exposure to antipsychotics, second generation (risperidone). Adjust dose.
Atomoxetine - increases exposure
Terbinafine is predicted to markedly increase the exposure to atomoxetine. Adjust dose. Study Atorvastatin → see statins Atovaquone → see antimalarials Atracurium → see neuromuscular blocking drugs, n
Corticosteroids - increases exposure
Dronedarone is predicted to increase the exposure to corticosteroids (methylprednisolone). Monitor and adjust dose.
Corticosteroids - increases concentration
Miconazole is predicted to increase the concentration of corticosteroids (methylprednisolone). Monitor and adjust dose.
Unknown (33)
Aspirin - decreases concentration
Corticosteroids are predicted to decrease the concentration of aspirin (high-dose) and aspirin (high-dose) increases the risk of gastrointestinal bleeding when given with corticosteroids.
Betablockers,selective - increases exposure
Terbinafine is predicted to increase the exposure to beta blockers, selective (metoprolol, nebivolol).
Choline Salicylate - decreases concentration
Corticosteroids are predicted to decrease the concentration of cholinesalicylate. Ciclesonide → see corticosteroids Ciclosporin → see TABLE 2 p. 1517 (nephrotoxicity), TABLE 16 p. 1521 (increased seru
Codeine - decreases efficacy
Terbinafineispredictedtodecreasetheefficacyofcodeine. oTheoretical
Corticosteroids - increases exposure
Cobicistat is predicted to increase the exposure to corticosteroids (beclometasone) (risk with beclometasone is likely to be lower than with other corticosteroids).
Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: class
About mometasone
Mometasone is a corticosteroid used to reduce inflammation and treat various allergic and skin conditions.
What it treats
- allergic rhinitis (hay fever)
- asthma
- skin conditions like eczema and psoriasis
How it works
It works by reducing inflammation in the body, which helps relieve symptoms.
Who it's for
It is for people suffering from allergies, asthma, or certain skin problems.
Drug class
Corticosteroids
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
About terbinafine
Terbinafine is an antifungal medicine used to treat fungal infections.
What it treats
- fungal nail infections
- ringworm (tinea)
- athlete's foot (tinea pedis)
- jock itch (tinea cruris)
How it works
It works by stopping the growth of fungi that cause infections.
Who it's for
It is suitable for adults and some children with fungal infections.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: Mometasonefuroate
BNF-referencedMometasone furoate is a potent corticosteroid used primarily for the management of asthma, allergic rhinitis, and nasal polyps. It exhibits anti-inflammatory, antipruritic, and vasoconstrictive properties, making it effective in reducing airway inflammation and alleviating symptoms of nasal congestion. Mometasone furoate is typically administered via inhalation or as a nasal spray, allowing for targeted delivery and minimizing systemic side effects.
Indications
- Management of asthma in adults and adolescents not adequately controlled with inhaled corticosteroids and short-acting beta-2 agonists
- Allergic rhinitis
- Nasal polyps
Dosage
Children: For children aged 12-17 years, initially 400 micrograms daily in 1-2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily if control is maintained.
Adults: 1 inhalation once daily; dosage may be increased to 400 micrograms twice daily if necessary.
Mechanism of action
Mometasone furoate works by binding to glucocorticoid receptors, leading to the modulation of gene expression. This results in the inhibition of pro-inflammatory cytokines and chemokines, thereby reducing inflammation in the airways and nasal passages. It also inhibits the activation of inflammatory cells such as eosinophils and mast cells, contributing to its therapeutic effects.
Pharmacodynamics
As a corticosteroid, mometasone furoate exhibits significant anti-inflammatory effects, which are crucial in the management of asthma and allergic conditions. The drug reduces airway hyper-responsiveness and decreases mucus production, leading to improved airflow and decreased symptoms such as wheezing and shortness of breath. Its rapid onset of action is beneficial for acute symptom relief.
Pharmacokinetics
Mometasone furoate is well-absorbed when administered by inhalation or nasal spray. It undergoes extensive first-pass metabolism in the liver, resulting in low systemic bioavailability. The drug is primarily excreted via the feces, with a small percentage eliminated through the urine. The half-life of mometasone furoate is approximately 5.8 hours, allowing for once-daily dosing in many cases.
Adverse effects
- Candida infection
- Nasal ulceration
- Throat irritation
- Headache
- Cough
Interactions
- Corticosteroids
- Beta2 agonists
Precautions
- Use with caution in patients with active or quiescent tuberculosis infections
- Monitor for signs of infection
- Use in hepatic impairment requires caution
Pregnancy
Use only if potential benefit outweighs risk-limited information available.
Breast-feeding
Avoid-present in milk in animal studies.
Storage
Store below 30°C. Protect from light and moisture.
Formulations
- {'form': 'Inhalation powder', 'strength': '200 micrograms per dose', 'brand': 'Asmanex Twisthaler'}
- {'form': 'Aqueous nasal spray', 'strength': '50 micrograms per dose', 'brand': 'Flixonase'}
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Clinical monograph: Terbinafine
BNF-referencedTerbinafine is an antifungal medication primarily used to treat dermatophyte infections, including tinea pedis (athlete's foot), tinea cruris (jock itch), tinea corporis (ringworm), and onychomycosis (fungal nail infections). It functions by inhibiting the enzyme squalene monooxygenase, which is crucial for ergosterol synthesis in fungal cell membranes. This results in compromised cell integrity and eventual fungal cell death. Terbinafine is available in various forms, including oral tablets and topical formulations such as creams and medicated nail lacquers.
Indications
- Tinea pedis (athlete's foot)
- Tinea cruris (jock itch)
- Tinea corporis (ringworm)
- Onychomycosis (fungal nail infections)
Dosage
Adults: For adults, the typical oral dosage for tinea infections is 250 mg once daily for 2 to
Mechanism of action
Terbinafine inhibits the enzyme squalene monooxygenase, preventing the conversion of squalene to 2,3-oxydosqualene, a vital step in ergosterol synthesis. This leads to reduced ergosterol levels, which are essential for fungal cell membrane integrity, and causes an accumulation of squalene, contributing to cell death.
Pharmacodynamics
As an allylamine antifungal, terbinafine disrupts fungal cell membrane synthesis by inhibiting squalene epoxidase. This action results in weakening of the cell wall and the formation of squalene-rich vesicles within the fungal cells. It has a long duration of action due to extensive tissue distribution and a long terminal elimination half-life. The therapeutic index is wide, making overdose uncommon, but liver function tests are recommended prior to treatment to mitigate the risk of hepatotoxicity.
Pharmacokinetics
Terbinafine is well absorbed after oral administration, with peak plasma concentrations occurring within 2 hours. It is extensively distributed in body tissues, particularly in skin and nails, where it accumulates. The elimination half-life ranges from 25 to 30 hours, allowing for once-daily dosing. Terbinafine is primarily metabolized by the liver and excreted in urine, with less than 5% of the dose excreted unchanged.
Adverse effects
- Nausea
- Diarrhea
- Abdominal pain
- Headache
- Rash
- Taste disturbance
- Liver function abnormalities
Interactions
- Moderate (increases exposure) with galantamine
- Moderate (increases exposure) with risperidone
- Moderate (increases exposure) with atomoxetine
- Moderate (increases exposure) with eliglustat
- Moderate (increases exposure) with fesoterodine
- Moderate (decreases exposure) with rifampicin
- Moderate (increases exposure) with fluoxetine
- Moderate (increases exposure) with centrally acting anticholinesterases
- Moderate (increases exposure) with second-generation antipsychotics
- Moderate (increases exposure) with tricyclic antidepressants
Precautions
- Use with caution in individuals with liver dysfunction
- Monitor liver function tests before and during therapy
- Avoid use in patients with a history of hypersensitivity to terbinafine or its components
- Caution in patients with renal impairment
Pregnancy
Manufacturer advises avoiding use unless potential benefit outweighs risk.
Breast-feeding
Manufacturer advises avoiding use unless potential benefit outweighs risk.
Storage
Store at room temperature, away from moisture and heat. Keep out of reach of children.
Formulations
- Tablets (250 mg)
- Cream (1%)
- Solution (1%)
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Clinical monograph: mometasone
BNF-referencedMometasone is a synthetic corticosteroid that exhibits medium potency and is primarily used for its anti-inflammatory, antipruritic, and vasoconstrictive properties. It is effective in the management of various inflammatory conditions, such as asthma, allergic rhinitis, and skin disorders. Mometasone works by reducing inflammation and suppressing immune responses, providing relief from symptoms associated with these conditions.
Indications
- Asthma
- Allergic rhinitis
- Skin conditions (e.g., eczema, dermatitis)
Dosage
Children: Refer to the BNF for Children for appropriate paediatric dosing guidelines.
Adults: Refer to the specific BNF guidelines for adult dosing, which may vary based on the condition being treated.
Mechanism of action
Mometasone exerts its anti-inflammatory effects by crossing cell membranes and binding with high affinity to specific cytoplasmic glucocorticoid receptors. This interaction diminishes the release of leukocytic acid hydrolases, prevents macrophage accumulation at inflamed sites, interferes with leukocyte adhesion to capillary walls, reduces capillary membrane permeability, and inhibits the release of histamine and kinin. Additionally, mometasone inhibits the formation of scar tissue and acts through phospholipase A2 inhibitory proteins, known as lipocortins, which control the synthesis of potent inflammatory mediators like prostaglandins and leukotrienes.
Pharmacodynamics
Mometasone demonstrates medium potency as a corticosteroid, effectively reducing inflammation without significant systemic absorption due to extensive hepatic metabolism. Its local effects are favored over systemic effects, making it suitable for chronic conditions like asthma, where immediate symptom relief is not expected. The onset of action may take 1 to 2 weeks for maximum improvement in asthma symptoms following inhalation. Discontinuation of mometasone may allow for sustained asthma stability for several days.
Pharmacokinetics
Mometasone is extensively metabolized in the liver, resulting in a low systemic bioavailability. Its pharmacokinetic profile includes rapid absorption and distribution, with a half-life that supports once-daily dosing in many cases. The lack of active metabolites contributes to its safety profile, minimizing systemic effects while providing effective local action.
Interactions
- cobicistat+mometasone: Unknown (increases exposure)
- idelalisib+mometasone: Unknown (increases exposure)
- clarithromycin+mometasone: Unknown (increases exposure)
Pregnancy
Mometasone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Breast-feeding
Caution should be exercised when administering mometasone to nursing mothers, as it is not known whether it is excreted in human milk.
Storage
Store at room temperature, away from light and moisture. Do not freeze.
Formulations
- Mometasone furoate nasal spray
- Mometasone furoate inhalation aerosol
- Mometasone furoate cream
- Mometasone furoate ointment
- Mometasone furoate lotion
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Molecular reference: mometasone
PubChem CID 441335Molecular formula: C22H28Cl2O4
Mechanism of action
Unbound corticosteroids cross cell membranes and bind with high affinity to specific cytoplasmic receptors. Inflammation is decreased by diminishing the release of leukocytic acid hydrolases, prevention of macrophage accumulation at inflamed sites, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A<sub>2</sub> inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Mometasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone.
Pharmacodynamics
Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. When glucocorticoids are discontinued, asthma stability may persist for several days or longer. Mometasone has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone. The clinical significance of these findings is unknown.
Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.
Molecular reference: Terbinafine
PubChem CID 1549008Molecular formula: C21H25N
Mechanism of action
Terbinafine inhibits the enzyme squalene monooxygenase (also called squalene epoxidase), preventing the conversion of squalene to 2,3-oxydosqualene, a step in the synthesis of ergosterol. This inhibition leads to decreased ergosterol, which would normally be incorporated into the cell wall, and accumulation of squalene. Generation of a large number of squalene containing vesicles in the cytoplasm may leach other lipids away from, and further weaken, the cell wall.
Pharmacodynamics
Terbinafine is an allylamine antifungal that inhibits squalene epoxidase (also known as squalene monooxygenase) to prevent the formation of ergosterol and cause an accumulation of squalene, weakening the cell wall of fungal cells. Terbinafine distributes into tissues and has a long terminal elimination half life, so the duration of action is long. Overdose with terbinafine is rare, even above the therapeutic dose, so the therapeutic index is wide. Patients taking oral terbinafine should have liver function tests performed prior to treatment to reduce the risk of liver injury.
Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.
This drug in other countries
The same active ingredient registered across other registries we cover - including different brands.
- ADSONE · East African Overseas
- AKRISIL · Akriti Pharmaceuticals
- Binafin · Seoul Pharma
- Binafin · Lincoln Pharmaceuticals
- Binafin · Lincoln Pharmaceuticals
- ELOCOM CREAM · Organon
- ADVASONE SPRAY ( MOMETASONE FUMERATE 0.52%) · Biodeal Pharmaceuticals
- DERMAV CREAM (Each tube contains Hydroquinone USP/ Tretinoin USP/ Mometasone furoate USP 2%w/v, 0.025%w/w, 0.10%w/w) · Mars Remedies
- ELICA OINTMENT · Jamjoom Pharmaceuticals
- ELICA-M CREAM (Each gram contains Mometasone Furoate/Miconazole Nitrate 0.1%w/w/2%w/w) · Jamjoom Pharmaceuticals
- ELICASAL OINTMENT · Jamjoom Pharmaceuticals
- ELOCOM CREAM · Organon
- AKRISIL · Akriti Pharmaceuticals
- AXCEL MOMETASONE 0.1% CREAM · Kotra Pharma
- BINAFIN · Lincoln Pharmaceutical Limited
- ELOCON · Organon
- MOMATE · Glenmark Pharmaceutical Ltd
- MOMATE · Glenmark Pharmaceutical Ltd